title: Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
abstract: OBJECTIVE
  To examine whether estrogen replacement therapy (ERT) affects clinical and cognitive responses to tacrine in women with Alzheimer's disease (AD).
  
  
  METHODS
  A 30-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial of tacrine in which a subgroup of women were receiving ERT prior to randomization.
  
  
  METHODS
  Women with mild to moderate-stage AD, at least 50 years of age, who were enrolled in the previously reported trial.
  
  
  METHODS
  Randomized assignment to placebo or to one of three ascending-dosage regimens of tacrine: maximum dosages of 80 mg/d, 120 mg/d or 160 mg/d.
  
  
  METHODS
  Alzheimer's Disease Assessment Scale-Cognitive Scale (ADASc), Clinician Interview-Based Impression of change (CIBI), Mini-Mental State Examination (MMSE), Caregiver's Impression of Change (CIC).
  
  
  RESULTS
  Of 318 women with evaluable data 14.5% were receiving ERT. Women completing the trial taking ERT and tacrine improved more than women not receiving ERT who were randomly assigned to tacrine or to placebo as assessed by the ADASc (p < 0.01), the CIBI (p = 0.02), the CIC (p = 0.006), and the MMSE (p = 0.07). They improved significantly on the ADASc (p = 0.01) using an intent-to-treat analysis.
  
  
  CONCLUSIONS
  Prior and continuing ERT may enhance response to tacrine in women with AD. Randomized trials are needed.
authors.affiliation: Department of Psychiatry and the Behavioral Sciences, School of Medicine, University of Southern California, Los Angeles 90033, USA.
authors.forename: L S
authors.initials: LS
authors.lastname: Schneider
authors.forename: M R
authors.initials: MR
authors.lastname: Farlow
authors.forename: V W
authors.initials: VW
authors.lastname: Henderson
authors.forename: J M
authors.initials: JM
authors.lastname: Pogoda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy / Q000628:therapy*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D004970:Estrone / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D013619:Tacrine / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D004966:Estrogens, Conjugated (USP); D018697:Nootropic Agents; D004970:Estrone; D004958:Estradiol; D013619:Tacrine; C017296:estrone sulfate